Hereditary angioedema in children and adolescents - A consensus update on therapeutic strategies for German-speaking countries.
Volker WahnWerner AbererEmel AygörenKonrad BorkWolfgang EberlMaria FaßhauerRenate KrügerMarkus MagerlInmaculada Martinez-SaguerPeter J SpaethPetra Staubach-RenzChristina Weber-ChrysochoouPublished in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020)
Currently, plasma-derived C1 inhibitor concentrates have the broadest approval status and are considered the best available option for on-demand treatment of HAE-C1-INH attacks and for short- and long-term prophylaxis across all pediatric age-groups in German-speaking countries. For on-demand treatment of children aged 2 years and older, recombinant C1-INH and bradykinin-receptor antagonist icatibant are alternatives. For long-term prophylaxis in adolescents, the parenteral kallikrein inhibitor lanadelumab has recently been approved and can be recommended due to proven efficacy and safety.